Related Experiment Videos

Facial signs of systemic disease

Michael M Nelson¹, Michael P Heffernan

¹Division of Dermatology, Washington University School of Medicine, Campus Box 8035, 4570 Children's Place, St. Louis, MO 63110, USA.

Facial Plastic Surgery Clinics of North America

|April 6, 2004

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.

The Journal of rheumatology·2015

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

Lancet (London, England)·2015

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.

Journal of the American Academy of Dermatology·2011

Nephrogenic systemic fibrosis: a review.

Journal of drugs in dermatology : JDD·2010

Innovative uses of rituximab in dermatology.

Dermatologic clinics·2010

Combining traditional systemic and biologic therapies for psoriasis.

Seminars in cutaneous medicine and surgery·2010

See all related articles